RankingsPricing
  1. US-listed companies
  2. NEUROCRINE BIOSCIENCES INC
  3. Financials
  4. Total cash & short-term investments

NEUROCRINE BIOSCIENCES INCNBIX

Market cap
$15.2B
P/E ratio
SummaryFinancials
Period EndTotal cash & short-term investments (Million USD)YoY (%)
Dec 31, 20241,084+4.28%
Dec 31, 20231,040+4.26%
Dec 31, 2022997-8.10%
Dec 31, 20211,085-23.49%
Dec 31, 20201,418+15.12%
Dec 31, 20191,232+5.69%
Dec 31, 20181,166+49.98%
Dec 31, 2017777+152.85%
Dec 31, 2016307-18.95%
Dec 31, 2015379+6.33%
Dec 31, 2014357+144.69%
Dec 31, 2013146-15.76%
Dec 31, 2012173+34.01%
Dec 31, 2011129

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)